Worse prognosis for sudden cardiac death events and progression to the burned-out phase in non-obstructive hypertrophic cardiomyopathy: insights from the REVEAL-HCM Registry
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM